Skip to main content

42 - References

References

42 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

  1. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Psychosis and schizophrenia: what monitoring is required? 2014 (last revised November 2021, checked January 2024); https://cks.nice.org.uk/topics/psychosis-­schizophrenia/prescribing-­ information/monitoring/#:~:text=References,What%20monitoring%20is%20required%3F,stabilized%20(whichever%20is%20longer).
  2. Bulteau S, et al. Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database. Expert Opin Drug Saf 2021; 20:225–233.
  3. Lydon A, et al. Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-­acting injectable antipsychotic medications: a cross-­sectional study. Ir J Psychol Med 2021; 38:40–48.
  4. Poojari PG, et al. Identification of risk factors and metabolic monitoring practices in patients on antipsychotic drugs in South India. Asian J Psychiatr 2020; 53:102186.
  5. Perry BI, et al. Prolactin monitoring in the acute psychiatry setting. Psychiatry Res 2016; 235:104–109.
  6. Burckart GJ, et al. Neutropenia following acute chlorpromazine ingestion. Clin Toxicol 1981; 18:797–801.
  7. Montgomery J. Ziprasidone-­related agranulocytosis following olanzapine-­induced neutropenia. Gen Hosp Psychiatry 2006; 28:83–85.
  8. Cowan C, et al. Leukopenia and neutropenia induced by quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:292–294.
  9. Marder SR, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349.
  10. Fenton WS, et al. Medication-­induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 2006; 163:1697–­1704.
  11. Taylor D, et al. Dopamine partial agonists: a discrete class of antipsychotics. Int J Psychiatry Clin Pract 2023; 27:272–284.
  12. Weissman EM, et al. Lipid monitoring in patients with schizophrenia prescribed second-­generation antipsychotics. J Clin Psychiatry 2006; 67:1323–1326.
  13. Cohn TA, et al. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492–501.
  14. Paton C, et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004; 110:299–305.
  15. Taylor D, et  al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005; 19:182–186.
  16. Citrome L, et al. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997–2004. Psychiatr Serv 2006; 57:1132–1139.
  17. Barnes T, et al. Evidence-­based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharm 2020; 34:3–78.
  18. Shah AA, et al. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract 2014; 20:196–206.
  19. Novotny T, et al. Monitoring of QT interval in patients treated with psychotropic drugs. Int J Cardiol 2007; 117:329–332.
  20. Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225–235.
  21. Hummer M, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997; 17:314–317.
  22. Erdogan A, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 2004; 34:83–89.
  23. Regal RE, et al. Phenothiazine-­induced cholestatic jaundice. Clin Pharm 1987; 6:787–794.
  24. Centorrino F, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002; 159:109–115.
  25. Gross A, et al. Clozapine-­induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry 2004; 37:119–122.
  26. Twaites BR, et al. The safety of quetiapine: results of a post-­marketing surveillance study on 1728 patients in England. J Psychopharmacol 2007; 21:392–399.
  27. Kelly DL, et al. Thyroid function in treatment-­resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66:80–84.

No comments to display

Back to top